29 result(s) for 'Immunofluorescence'
21 - 29 of 29 results for 'Immunofluorescence'
Sort by
Show
In recent years, digital pathology has gone from an intriguing idea to an integral part of how academic and commercial labs operate. Join Leica Biosystems and Procia Digital Pathology as they discuss why institutions are going digital today and how they...
Biomarkers
AE1/AE3 (1)
AMACR (2)
BCL6 (1)
CD163 (2)
CD20 (2)
CD3 (9)
CD4 (5)
CD68 (5)
CD8 (10)
CDX2 (2)
CK20 (5)
Ck5 (4)
...
The content of this webinar will encompass detailed technical descriptions of novel and state of the art methods to decalcify tissue samples that will be embedded in paraffin or for frozen sectioning for molecular and nucleic acid analysis for basic research...
Introduction to immuno oncology
1. Introduction to Immuno-Oncology Michael Bates, MD Oncology Strategy, Medical and Scientific Affairs Cepheid Sunnyvale, CA Cepheid and Leica Biosystems are Danaher Companies
2. Overview • History of Immuno-Oncology • Types of Immunotherapy • Immunomodulatory agents • Personalized Cancer Vaccines • CAR-T cell therapy • Immune Checkpoint Inhibitors • Focus: Immune Checkpoint Biomarkers
3. Evolution of Cancer Immunotherapy • William Coley – 1890s surgeon • Coley’s toxin… • BCG, IFN-alpha, IL-2 • IL-2 applications in melanoma and RCC proved that advanced metastatic cancers can be controlled in some patients by stimulating T cells with cytokines • Critical development • CTLA-4 shown to be inhibitory for T cell responses by James Allison and Jeff Blu...
It’s Time for TIME Alexander “Sandy” Borowsky Professor of Pathology and Laboratory Medicine Center for Immunology and Infectious Diseases
Disclosures Bristol-Meyers Squibb/Celgene: Funded through Investigator Sponsored Research (ISR) program. Discovery proposal. Leica/Aperio: Funded to run the “Genesis” study for primary diagnosis from whole slide images. Honorarium for this presentation. Histolix: Slide-free histology (Levenson and Fereidouni). Pfizer: Pfizer Protocol A9001502, Treatment Resistance Following Therapies (TRANSLATE) site PI. Agenda: In contracting to join the “FLEX” registry. None of these has actually paid me, only funding for the research projects.
Objectives • Introduction into the complexity of the TIME and the development of new cancer treatments though di...